Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

Mary K. Lindemuth, David Euhus

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma. Recent Findings: Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal. Summary: In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.

Original languageEnglish (US)
Pages (from-to)332-334
Number of pages3
JournalCurrent Breast Cancer Reports
Issue number4
StatePublished - Dec 1 2019


  • Breast implant-associated lymphoma
  • Current guidelines
  • Diagnosis
  • Pathogenesis
  • Textured breast implants
  • Treatment

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma'. Together they form a unique fingerprint.

Cite this